HIV patients with belly fat who took tesamorelin were more likely to lose at least 8% of their visceral fat than those who took a placebo.

HIV patients with belly fat who took tesamorelin had a 69% chance of losing at least 8% visceral fat, while those on placebo had only a 33% chance, showing a clear benefit from the drug.

This drug only helped people whose belly fat went down a lot—so if your belly fat didn’t shrink, we don’t know if it would help your muscles.

HIV patients with belly fat who responded to tesamorelin saw better lean muscle quality in their abdominal and rectus muscles, with improvements of 1.39 and 1.78 units respectively compared to placebo after 26 weeks.

HIV patients with belly fat who responded to tesamorelin had more lean muscle mass in all four trunk muscles, with increases between 0.64 and 1.08 cm² compared to placebo after 26 weeks.

For HIV patients with belly fat who responded to tesamorelin, the drug was linked to better muscle density in four trunk muscles, with improvements between 1.56 and 4.86 units compared to placebo after 26 weeks.